Geistlich Pharma North America, Inc.
Terri Riley Hudak, PMP has a diverse and extensive work experience. Terri is currently serving as the Vice President of Clinical Research, Education, and Project Management at Geistlich Biomaterials - North America since July 2022. Prior to this role, Terri worked as a Commissioner at Union County Improvement Authority from February 2021 onwards.
Before joining Geistlich Biomaterials, Terri held various positions at Orthofix. Terri was the Vice President of Marketing, Biologics from July 2021 to August 2022, responsible for overseeing marketing strategies. Earlier, they served as the Senior Director of Marketing, Biologics from January 2016 to July 2021 and as the Director of Marketing from January 2014 to January 2016.
Terri's previous experience includes working at MTF as a Product Manager from May 2011 to January 2014. Terri managed multiple market portfolios, including Biologics, Sports, and Amnion. Additionally, they worked as a Project Manager and was PMP certified from January 2010 to May 2011. At MTF, they also served as a Scientist, Assistant Scientist, Sr. Research Technician, and Research Technician in earlier roles.
Terri started their career as a QA Technician at Johnson & Johnson in September 2003, followed by a role as a Research Associate at Celgene Cellular Therapeutics from September 2002 to September 2003. Prior to entering the healthcare industry, they worked as a Sr. Credit and Order Operations Specialist at Verizon Wireless from September 2001 to September 2002.
Terri Riley Hudak, PMP, holds a Masters degree in Biology from Rutgers-NJIT, which was obtained between 2005 and 2007. Prior to that, they completed their Bachelor of Science degree in Biological Sciences at the University of Vermont from 1997 to 2001. Terri also possesses additional certifications, including a Marketing Strategy Certificate from Cornell University and the PMP certification from the Project Management Institute, which was obtained in 2010.
Geistlich Pharma North America, Inc.
Geistlich Pharma North America, Inc., is an affiliate of Geistlich Pharma AG who produce and distribute medical devices and pharmaceuticals for regenerative medicine in Wolhusen and Root, Switzerland. The Swiss company forms part of the Geistlich group which has been in family hands since 1851. Geistlich Pharma and its 3 business units Geistlich Biomaterials, Geistlich Surgery, Geistlich Medical have 10 subsidiaries and global distribution, over 500 employees worldwide and is a world leader in regenerative dentistry through its business unit Geistlich Biomaterials. Geistlich continues to lead oral regeneration based upon our history of quality, scientific collaboration, and manufacturing excellence. Every Geistlich biomaterial is intentionally designed for a specific application and carefully engineered to preserve its natural structures. Today, our full product portfolio of Bone Substitutes, Membranes, and Matrices increases clinical flexibility and expands treatment options in a variety of therapeutic areas. Geistlich Bio-Oss®: Derived from bovine bone and preserved through a unique, patented process, making it highly similar to human bone. Geistlich Bio-Oss® remains the essential choice among an expanding range of therapeutic areas through its unique properties and reliable clinical outcomes. Geistlich Bio-Gide®: A unique bilayer collagen membrane designed to ensure optimal regenerative healing of bone and soft tissue. It provides excellent wound stability and graft containment with optimal protection for bone regeneration. Geistlich Mucograft®: A collagen matrix designed for gain of keratinized tissue and recession coverage where open healing is required. Geistlich Fibro-Gide®: The first volume-stable collagen matrix designed for soft-tissue augmentation around natural teeth and implants as a submerged scaffold where an increase in soft-tissue thickness is clinically desired.